VALANX Biotech
Site-specific conjugation for superior ADCs
Founded 2017 · $5.8M raised
- Employees
- 11–50
- Founded
- 2017
- Website
- valanx.bio
- Total Funding
- $5.8M
- Last Round
- $3.3M Series AMar 2026
- Rounds
- 2
About
VALANX Biotech is a Vienna-based biotechnology company developing next-generation antibody-drug conjugates (ADCs) and protein conjugates using its proprietary GoldenSite platform. GoldenSite enables site-specific conjugation, placing ADC payloads in structurally shielded positions on antibodies to improve efficacy and stability compared to conventional random conjugation methods. The company partners with pharmaceutical companies to advance the development of superior therapeutic conjugates. VALANX has grown its scientific team significantly since founding and brought on a new Chief Scientific Officer in late 2025.
Summary
VALANX Biotech is a company, founded in 2017. It has raised $5.8M in total across 2 rounds, most recently a $3.3M Series A round in Mar 2026. Investors include XISTA Science Ventures, Foundation Fournier-Majoie and FUJIFILM Corporation.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2026
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
